June 2017

Report: Patients want biosimilars and biologics testing consistency

Friday, June 30, 2017

Health Stories Project—Insights, a new healthcare market intelligence company dedicated to magnifying the patient voice to influence decision making and support movement toward patient-centricity, has announced the launch of its Insights Reports with the publication of a report titled “Biosimilars: Patient Understanding and Attitudes.” The research showed that 81% of patients believe biosimilars and biologics should require the same type and level of testing, and the response is even higher among women (83%) and consumers 55 and older (92%). Among patients not using biologics, more than half said they were interested in learning more about biosimilars.

[Read More]

Roche acquires mySugr to form digital diabetes management open platform

Friday, June 30, 2017

Roche and mySugr announced that the two partners have signed an agreement under which Roche acquired all shares of mySugr. Counting more than one million users globally, mySugr is one of the leading mobile diabetes platforms in the market and will become an integral part of Roche’s new patient-centered digital health services platform in diabetes care. The acquisition allows Roche to expand its leading position in the area of diabetes management.

[Read More]

Philips to acquire The Spectranetics Corporation

Friday, June 30, 2017

Royal Philips, a global leader in health technology, and The Spectranetics Corporation, a U.S.-based global provider of vascular intervention and lead management solutions, have entered into a definitive merger agreement. Pursuant to the agreement, Philips will commence a tender offer to acquire all of the issued and outstanding shares of Spectranetics for $38.50 per share, to be paid in cash upon completion. This represents a 27% premium to Spectranetics closing price on June 27, 2017. The implied enterprise value is approximately EUR 1.9 billion, inclusive of Spectranetics’ cash and debt. The board of directors of Spectranetics has approved the transaction and recommends the offer to its shareholders. The transaction is expected to close in the third quarter of 2017.

[Read More]

Pfizer breaks ground on new R&D facility in Missouri, to hire 80

Thursday, June 29, 2017

Pfizer, a biopharmaceutical company, broke ground on a state-of-the art Research and Development (R&D) and process development facility at 875 W. Chesterfield Parkway, Chesterfield, MO. The new campus will be owned by Pfizer and will bring together more than 450 employees who currently work at multiple locations which the company leases in the St. Louis area. Pfizer expects to hire an additional 80 employees over the coming years to support research at the site. Construction is expected to be complete by mid-2019.

[Read More]

Parexel again named to Forbes America’s Best Employers List

Thursday, June 29, 2017

Parexel International, a global biopharmaceutical services organization, announced that for the second year in a row, Forbes has named the company to its America’s “Best Employers” list. The list recognizes the top 300 midsized employers and top 500 large employers. Results are based on anonymous survey responses from 30,000 U.S. employees, with the most weighted factor being how likely they were to recommend their organizations to others.

[Read More]